Yoshida T, Nakanishi J, Ito K, Kobayashi K, Ohtake S, Nakamura S, Matsuda T, Nakagoshi T, Natori K, Nakamura E
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):984-9.
Nineteen patients with refractory non-Hodgkin's lymphoma were treated with a combination of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (150-200 mg/m2), aclacinomycin (15 mg/m2), etoposide (70 mg/m2 i.v. or 100 mg/m2 p.o) and prednisolone (20 mg/m2) (ABEP regimen). Patients who achieved complete remission (CR) received 10 courses of consolidation therapy with ACOP-E chemotherapy (adriamycin, cyclophosphamide, vincristine, prednisolone and etoposide). Seven patients achieved CR and three partial remission. Twelve patients with fresh non-Hodgkin's lymphoma stage IV were treated with ABEP regimen. CR was obtained in eight patients (66.7%). The median duration of CR was 11+ alpha months. Hematological toxicity was a dose-limiting factor but this was manageable.
19例难治性非霍奇金淋巴瘤患者接受了N4-山嵛酰-1-β-D-阿拉伯呋喃糖基胞嘧啶（150-200mg/m²）、阿克拉霉素（15mg/m²）、依托泊苷（静脉注射70mg/m²或口服100mg/m²）和泼尼松龙（20mg/m²）联合治疗（ABEP方案）。达到完全缓解（CR）的患者接受了10个疗程的ACOP-E化疗巩固治疗（阿霉素、环磷酰胺、长春新碱、泼尼松龙和依托泊苷）。7例患者达到CR，3例部分缓解。12例新发非霍奇金淋巴瘤IV期患者接受ABEP方案治疗。8例患者（66.7%）获得CR。CR的中位持续时间为11+α个月。血液学毒性是剂量限制因素，但可以控制。
